Cosmo Pharmaceuticals N.V.
CMOPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $51,720 | $130,551 | $136,237 | $49,119 |
| % Growth | -60.4% | -4.2% | 177.4% | – |
| Cost of Goods Sold | $25,571 | -$3,285 | $23,150 | $20,469 |
| Gross Profit | $26,149 | $133,836 | $113,087 | $28,650 |
| % Margin | 50.6% | 102.5% | 83% | 58.3% |
| R&D Expenses | $17,997 | -$10,451 | $10,824 | $10,523 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $14,264 | -$8,911 | $16,323 | $28,181 |
| Sales & Mktg Exp. | $0 | $953 | $0 | $0 |
| Other Operating Expenses | -$4,701 | $91,270 | -$1,014 | -$9,569 |
| Operating Expenses | $27,560 | $71,908 | $26,133 | $29,135 |
| Operating Income | -$1,411 | $61,928 | $86,954 | -$977 |
| % Margin | -2.7% | 47.4% | 63.8% | -2% |
| Other Income/Exp. Net | $741 | $2,691 | $1,794 | -$1,164 |
| Pre-Tax Income | -$670 | $64,619 | $88,748 | -$2,141 |
| Tax Expense | $1,360 | $7,486 | $12,690 | $4,077 |
| Net Income | -$2,006 | $57,245 | $75,991 | -$6,418 |
| % Margin | -3.9% | 43.8% | 55.8% | -13.1% |
| EPS | -0.13 | 3.45 | 4.7 | -0.4 |
| % Growth | -103.8% | -26.6% | 1,275% | – |
| EPS Diluted | -0.13 | 3.43 | 4.71 | -0.4 |
| Weighted Avg Shares Out | 15,921 | 16,359 | 16,151 | 16,064 |
| Weighted Avg Shares Out Dil | 15,971 | 16,418 | 16,150 | 16,064 |
| Supplemental Information | – | – | – | – |
| Interest Income | $658 | $726 | $943 | $992 |
| Interest Expense | $0 | $53 | $0 | -$561 |
| Depreciation & Amortization | $6,263 | $4,993 | $7,292 | $6,642 |
| EBITDA | $4,852 | $71,459 | $94,246 | $5,665 |
| % Margin | 9.4% | 54.7% | 69.2% | 11.5% |